Health data and analytics firm Health Catalyst on Thursday reported a second-quarter revenue decline and reduced its full-year outlook after divesting its revenue-cycle business, Vitalware, a move executives said was intended to sharpen strategic focus and shore up the company’s balance sheet.
Quarterly results and strategic shift
The company posted $70.49 million in revenue for the quarter, a 12.7% decline from the year-ago period but slightly above analyst estimates. Adjusted earnings per share were $0.04, while adjusted EBITDA totaled $9.92 million, representing a 14.1% margin.
Management said the revenue decrease reflected client migrations and reduced demand for lower-margin services, and highlighted the decision to sell Vitalware as a deliberate step to concentrate on higher-conviction areas.
“necessary to focus on areas of highest conviction, despite the near-term revenue impact.”
The company’s chief executive framed the divestiture as both a strategic realignment and a tool to address financial leverage. Executives said the transaction delivered immediate benefits, including a substantial reduction in debt and a "cleaner" balance sheet, though it weighed on near-term revenue.
Guidance and metrics
Health Catalyst trimmed its full-year revenue midpoint to $247.5 million from a prior midpoint of $262.5 million. Full-year EBITDA guidance was set at a midpoint of $18.25 million, well below the consensus analyst estimate of approximately $32.09 million.
Other operating metrics disclosed by the company included an operating margin of -51.8%, a deterioration from -46% in the same quarter last year, and quarter-end billings of $54.75 million, down 28.1% year over year. The company’s market capitalization stood at about $134.7 million.
| Metric | Reported |
|---|---|
| Revenue (Q2) | $70.49 million |
| Adjusted EPS | $0.04 |
| Adjusted EBITDA | $9.92 million (14.1% margin) |
| Full-year revenue midpoint | $247.5 million |
| Full-year EBITDA midpoint | $18.25 million |
Management tone and analyst scrutiny
Executives described the company as being in the early phase of a multiyear transformation, urging caution about persistent revenue headwinds. Management emphasized investments in personnel and core products even as they pared back the business to its highest-priority areas.
On the earnings call, analysts pressed management about the drivers of the lowered guidance and how much of the change stemmed directly from the Vitalware sale. The chief financial officer acknowledged that removing Vitalware was a primary factor but also noted increased investment spending as a contributor.
- Strategic consequence: The sale reduced leverage and simplified the balance sheet, according to executives.
- Operational challenge: Revenue and billings fell, and the company signaled a period of restrained near-term growth.
- Investor focus: Attention will center on whether management’s investments and refocused product set can restore growth over the next several quarters.
The company’s combination of one-time balance-sheet improvements and ongoing revenue pressure underscores a broader tension facing health-tech firms: aligning product portfolios and capital structure while maintaining growth amid shifting health-system budgets and client transitions. Investors and health-system customers will likely watch upcoming quarters closely for evidence that the strategy stabilizes margins and revenue trends.
Reporting on quarterly results and executive commentary offers a snapshot of Health Catalyst’s current position, but management’s characterization of a multiyear transformation indicates the firm expects this to be an extended process rather than an immediate turnaround.
